UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 24.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 100,020 shares of the specialty pharmaceutical company's stock after buying an additional 19,824 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.18% of Supernus Pharmaceuticals worth $3,617,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Raiffeisen Bank International AG purchased a new position in shares of Supernus Pharmaceuticals during the fourth quarter worth approximately $25,000. Smartleaf Asset Management LLC increased its holdings in Supernus Pharmaceuticals by 219.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock worth $47,000 after purchasing an additional 870 shares during the period. Mark Sheptoff Financial Planning LLC purchased a new position in Supernus Pharmaceuticals during the 4th quarter worth $52,000. Headlands Technologies LLC raised its position in Supernus Pharmaceuticals by 203.0% during the 4th quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company's stock valued at $55,000 after purchasing an additional 1,015 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. purchased a new stake in shares of Supernus Pharmaceuticals in the 4th quarter worth $72,000.

Supernus Pharmaceuticals Stock Performance

Supernus Pharmaceuticals stock traded up $0.81 during mid-day trading on Friday, reaching $33.15. 354,750 shares of the company were exchanged, compared to its average volume of 478,015. The firm has a market cap of $1.86 billion, a P/E ratio of 30.98 and a beta of 0.71. The business has a fifty day moving average of $31.95 and a 200 day moving average of $34.45. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.53 and a 12-month high of $40.28.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on SUPN shares. Wall Street Zen raised Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, May 16th. Cantor Fitzgerald reiterated a "neutral" rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.